Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation-Reference-Cited by-同舟云学术

Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation

Published:2022-06-11 Issue:9 Volume:29 Page:2792-2800
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Li Rui¹,Li Cong¹²,Huang Qiao³,Liu Zifeng⁴,Chen Jingjing⁴,Zhang Bingjun¹,Liu Chunxin¹,Shu Yaqing¹^ORCID,Wang Yuge¹,Kermode Allan G.¹⁵⁶^ORCID,Qiu Wei¹^ORCID

Affiliation:

1. Department of Neurology Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

2. Department of Neurology Zhongda Hospital of Southeast University Nanjing China

3. Department of Neurology Zhaoqing No. 2 People's Hospital Zhaoqing China

4. Clinical Data Center Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

5. Centre for Neuromuscular and Neurological Disorders, Department of Neurology, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre University of Western Australia Perth WA Australia

6. Institute of Immunology and Infectious Diseases Murdoch University Perth WA Australia

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15425

Reference19 articles.

1. Neurodegeneration in multiple sclerosis and neuromyelitis optica

2. New therapies for neuromyelitis optica spectrum disorder